The story of Viagra, originally marketed by copyright, presents a intricate case study for backers considering the pharmaceutical sector. Despite its initial success and generation of billions in revenue , the exclusivity lapse has opened the way for competing medications, greatly reducing income opportunities. This shift raises questions about the